BSE filing, NSE: GLAXO. Summary written from the filing by ALFA Finder's alert engine.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,575.10
- Market cap
- ₹43,624 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 40.8×Sector 47.2×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Other Announcement
GSK Pharmaceuticals appointed M/s. Walker Chandiok & Co. LLP as Statutory Auditor, effective 1 April 2027 for a 60-month term. The appointment was approved at the board meeting held on 3 November 2026.
- Execution
- 1 April 2027 for 60 months
GlaxoSmithKline Pharmaceuticals Results Update
GSK Pharmaceuticals reported Q2 FY27 media release showing revenue of INR 1180 crore (up 21%) and PAT of INR 335 crore (up 31%). The release also announces the upcoming BLENREP launch in India.
GlaxoSmithKline Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.9 Cr, Up 30.4% YoY
GlaxoSmithKline Pharmaceuticals Ltd reported revenue from operations of ₹1,184 Cr (+20.8% YoY) and net profit of ₹335.9 Cr (+30.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.9 Cr · +30.4% YoY
GlaxoSmithKline Pharmaceuticals Board Meeting Date
GlaxoSmithKline Pharmaceuticals Limited will hold a board meeting on 3rd November 2026 to consider and approve its unaudited financial results for the quarter ended 30th September 2026.
GlaxoSmithKline Pharmaceuticals Other Announcement
GlaxoSmithKline Pharmaceuticals Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI listing regulations.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
Other management change announcements
All →Praveg Management Change
Praveg Limited's Company Secretary and Compliance Officer, Mukeshkumar Chaudhary, resigned effective November 3, 2026. Himalay Dudharejiya was appointed in his place from the same date.
DAM Capital Advisors Management Change
DAM Capital Advisors appointed Kishor Purshottam Thakkar as Non-Executive Independent Director for 60 months. Rajendra Prabhakar Chitale's tenure as Non-Executive Independent Director completed, with both changes effective 14 December 2026.
Vijaya Diagnostic Centre Management Change
Vijaya Diagnostic Centre appointed Rahul Jain as Company Secretary and Compliance Officer, designated KMP, effective November 03, 2026. The appointment follows the Nomination and Remuneration Committee's recommendation.
Endurance Technologies Management Change
Endurance Technologies' Compliance Officer Sunil Lalai resigned, effective 16 Nov 2026. Mandar Velankar is appointed Compliance Officer from the same date.
Transrail Lighting Management Change
Transrail Lighting appointed three senior management personnel and recorded two departures, effective 3 November 2026. Changes cover civil, poles and lighting, and supply chain roles.
Dipna Pharmachem Management Change
Dipna Pharmachem's board appointed two Additional Non-Executive Independent Directors and reconstituted the Audit, Nomination & Remuneration and Stakeholders Relationship Committees effective 3 November 2026. No capital, money, or business event is involved.